Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CHTR1D
The experimentally established mechanism targets of Ergotamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.93 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.93 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.93 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.93 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.93 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.93 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.93 |
| ▸ | DRD2 | P14416 | 6/20 | 0.93 |
| ▸ | HTR2A | P28223 | 6/20 | 0.93 |
| ▸ | HTR2C | P28335 | 6/20 | 0.93 |
| ▸ | HTR6 | P50406 | 6/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.93 |
| ▸ | DRD3 | P35462 | 5/20 | 0.93 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.93 |
| ▸ | DRD1 | P21728 | 4/20 | 0.93 |
| ▸ | HTR2B | P41595 | 4/20 | 0.93 |
| ▸ | HTR1A | P08908 | 4/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.93 |
| ▸ | HTR1B | P28222 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergotamine SCHEMBL134885 | 1.00 | CYP3A4 (0.93) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29358869 | 1.00 | CYP3A4 (0.93) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL8045 | 1.00 | CYP3A4 (0.93) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29420131 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL22171508 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL29567350 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL783017 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL783018 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL1483 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 | |
| Ergotamine SCHEMBL18134607 | 0.97 | CYP3A4 (1.00) | CYP3A4DRD2HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4550 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240216486-A1 | INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES | REVANCE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | claimed |
| US-20240122855-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2024-04-18 | — | — | US | claimed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | claimed |
| CN-117295489-A | Compositions, devices and methods for treating respiratory disorders | 呼吸解决方案股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-117279681-A | Product delivery device and method | 呼吸解决方案股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| EP-4255541-A1 | PRODUCT DELIVERY DEVICES AND METHODS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4255390-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING RESPIRATORY DISORDERS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-5420197-A | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | HYDROMER, INC. (US) | 1995-05-30 | — | — | US | claimed |
| EP-0390911-B1 | LOW-MELTING MOLDABLE PHARMACEUTICAL EXCIPIENT AND ITS USE WITH PHARMACEUTICAL COMPOSITIONS | ZETACHRON INC (US) | 1995-03-01 | — | — | EP | claimed |
| US-5244668-A | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith | ZETACHRON, INC. (US) | 1993-09-14 | — | — | US | claimed |
| US-5139790-A | Buccal drug delivery | ZETACHRON, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0390911-A4 | LOW-MELTING MOLDABLE PHARMACEUTICAL EXCIPIENT AND DOSAGE FORMS PREPARED THEREWITH | — | 1991-10-23 | — | — | EP | claimed |
| EP-0390911-A1 | LOW-MELTING MOLDABLE PHARMACEUTICAL EXCIPIENT AND DOSAGE FORMS PREPARED THEREWITH. | ZETACHRON INC (US) | 1990-10-10 | — | — | EP | claimed |
| WO-1990003776-A1 | LOW-MELTING MOLDABLE PHARMACEUTICAL EXCIPIENT AND DOSAGE FORMS PREPARED THEREWITH | ZETACHRON, INC. (US) | 1990-04-19 | — | — | WO | claimed |
| US-4479889-A | TREATING TO MAKE INEDIBLE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-10-30 | — | — | US | claimed |
| US-4235236-A | Device for dispensing drug by combined diffusional and osmotic operations | ALZA CORPORATION (US) | 1980-11-25 | — | — | US | claimed |
| US-4153700-A | Treatment of the acute after-effects resulting from alcohol ingestion | LAKE SHORE ROENTGENOLOGY LTD. (US) | 1979-05-08 | — | — | US | claimed |